.jpeg)
2026-03-17 07:09:35
Brigatinib is a second-generation ALK inhibitor designed for ALK-positive non-small cell lung cancer patients. This article details drug mechanism, indications, side effect management, and latest clinical advances to support scientific medication use.
2026-03-17 02:50:08
Repotrectinib is a ROS1/NTRK targeted anticancer drug developed by Bristol-Myers Squibb, approved in China in 2024. This article details drug origin, pricing, supply channels, and eligible patient populations for comprehensive medication reference.
2026-03-16 07:12:44
Ceritinib is a common oral targeted medication for non-small cell lung cancer. This article details drug storage temperature, environmental requirements, expiration date identification, and abnormal condition handling for safe medication use.
2026-03-16 06:56:17
Selumetinib is an oral MEK inhibitor for treating Type 1 Neurofibromatosis (NF1). This article details drug mechanism, SPRINT clinical data, indications, dosage guidelines, and safety management.
2026-03-12 06:53:06
Alectinib is a second-generation ALK inhibitor for treating ALK-positive advanced non-small cell lung cancer. This article comprehensively analyzes its first and second-line treatment efficacy, brain metastasis control, resistance issues, and safety profile for patients and healthcare professionals.
2026-03-11 07:15:54
Repotrectinib, as a next-generation ROS1/NTRK tyrosine kinase inhibitor, has attracted significant attention regarding its generational classification. This article professionally analyzes Repotrectinib's generation positioning, core characteristics, and treatment sequence based on the development history of ROS1 inhibitors.
2026-03-10 01:38:34
Goserelin, as a GnRH analog, is widely used for prostate cancer, breast cancer, and gynecological diseases, but may cause side effects like hot flashes and bone density loss. 2025 clinical guidelines recommend light, nutritious, balanced diet with high protein and calcium, avoiding spicy and processed foods. Special populations need personalized management to enhance treatment tolerance and quality of life.
2026-03-10 01:22:25
Breakthrough research published in "Genes & Immunity" (2025) identifies folate metabolism-related gene CYP26A1 as a clinical immune target for colorectal cancer. Multi-omics analysis and experimental validation reveal CYP26A1's role in promoting tumor proliferation, metastasis, and immunosuppressive microenvironment, offering new precision treatment directions for patients.
2026-03-06 05:41:28
Decoding Inavolisib’s breakthrough in PIK3CA-mutant HR+/HER2- breast cancer: INAVO120 trial data, quality-of-life preservation, and expansion to HER2+ disease.
2026-02-28 06:38:41
Master Regorafenib (Stivarga) dosing: low-fat breakfast, fixed timing, dose escalation strategy for optimal efficacy and reduced side effects in liver and colorectal cancer.
2026-02-26 03:14:05
Erlotinib,also known as Tarceva,is a classic drug of the epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)family and has a milestone in the precision treatment of lung cancer.Its core indication is non-small cell lung cancer(NSCLC)patients carrying EGFR sensitive mutations.With the advantages of precise targeting and definite efficacy,it effectively breaks the limitations of traditional chemotherapy,promotes the new era of lung cancer treatment from"extensive chemotherapy"to"precise targeting",and brings longer survival and better quality of life to countless advanced lung cancer patients.
2026-01-26 06:00:27
Ibrutinib (generic name: Ibrutinib) is a targeted therapy prescription drug that exerts therapeutic effects by inhibiting Bruton's tyrosine kinase (BTK).
